cjc 1295 without dac ipamorelin CJC-1295 & 10mg cjc 1295 without dac ipamorelin

[8] [9] The net effect of combining these agents on glycaemic control is unpredictable and could result in dysglycaemia particularly hyperglycaemia or worsening insulin resistance especially in individuals with pre-existing impaired glucose tolerance or type 2 diabetes

Ipamorelin Wikipedia (encyclopedic synthesis of peer-reviewed literature).

Start: 300 mcg daily for weeks 12

Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)

Thankfully, these symptoms are typically short-lived and manageable